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A B S T R A C T
Purpose
Application of current nodal status classification is complicated in lobular breast carcinoma
metastases. The aim of this study was to define the optimal interpretation of the pTNM
classification in sentinel node (SN) –positive patients to select patients with limited or with a high
risk of non-SN involvement.
Patients and Methods
SN metastases of 392 patients with lobular breast carcinoma were reclassified according to
interpretations of the European Working Group for Breast Screening Pathology (EWGBSP) and
guidelines by Turner et al, and the predictive power for non-SN involvement was assessed.
Results
Reclassification according to definitions of EWGBSP and Turner et al resulted in different pN
classification in 73 patients (19%). The rate of non-SN involvement in the 40 patients with isolated
tumor cells according to Turner et al and with micrometastases according to EWGBSP was 20%,
which is comparable to the established rate for micrometastases. The rate of non-SN involvement
in the 29 patients with micrometastases according to Turner et al and with macrometastases
according to EWGBSP was 48%, which is comparable to the established rate for macrometasta-
ses. Therefore, the EWGBSP method to classify SN tumor load better reflected the risk of non-SN
involvement than the Turner et al system.
Conclusion
Compared with the guidelines by Turner et al, the EWGBSP definitions better reflect SN
metastatic tumor load and allow better differentiation between patients with lobular breast
carcinoma who have a limited or a high risk of non-SN metastases. Therefore, we suggest using
the EWGBSP definitions in these patients to select high-risk patients who may benefit from
additional local and/or systemic therapy.
J Clin Oncol 28:999-1004. © 2010 by American Society of Clinical Oncology
INTRODUCTION
The introduction of the sentinel node (SN) proce-
dure in patients with breast cancer has led to an
increaseddetection rate of small lymphnodemetas-
tases1,2 because of an intensive pathology protocol
that includes step sectioning and immunohisto-
chemistry.3 This phenomenon is reflected by the
current definitions of the International Union
Against Cancer (UICC) Tumor Lymph Node Me-
tastasis (TNM)ClassificationofMalignantTumors4
andthe sixtheditionof theAmericanJointCommit-
tee on Cancer (AJCC) Staging Manual,5 which
distinguish between isolated tumor cells (ITCs),mi-
crometastases, and macrometastases on the basis of
metastatic cluster size.
Although there is no consensus whether the
distinction between ITCs and micrometastases
has prognostic significance6-8 it is important, as it
directly affects decisions with regard to completion
axillary lymph node dissection and adjuvant sys-
temic therapy. Patients with SN ITC are gener-
ally considered and treated as node negative (ie,
pN0[i]), whereas patients with micrometastases
(ie, pN1mi) and macrometastases (pN1) are staged
as node-positive. These patients commonly receive
additional axillary treatment and, in certain circum-
stances, adjuvant systemic therapy.
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Currently, the UICC and AJCC definitions of ITC, micrometas-
tases, and macrometastases are imprecise; therefore, different inter-
pretations of the definitions exists, which has resulted in suboptimal
reproducibility of nodal staging.9-13 Although both the UICC and
AJCC systems use size of the largest metastatic cluster, the UICC also
considers some qualitative features ofmetastatic deposits (ie, prolifer-
ation and extravasation). Furthermore, there is no generally accepted
definition for a cluster,which complicates sizemeasurement in case of
multiple clusters and/or cells.This isparticularly important inpatients
with invasive lobular breast carcinoma, because these metastases fre-
quently consider multiple, scattered, small clusters and/or single cells
in both the sinus and the parenchyma.
Thus,newpathologicnodal staging criteria shouldbe introduced
to arrive at better reproducibility and, consequently, optimal thera-
peutic decision making. The European Working Group for Breast
ScreeningPathology (EWGBSP)offered some refinements of the cur-
rent nodal staging definitions,9 which resulted in improved (although
still suboptimal) reproducibility (, 0.49). Turner et al11 recently re-
ported alternate interpretations of the same definitions, which re-
sulted in enhanced interobserver agreement (, 0.92), even in the
classification of lobular carcinoma SNmetastases. However, a poten-
tial disadvantage of the refinements by Turner et al11 is the classifica-
tionofhighSNtumor loaddispersedpatternmetastases as ITC,which
might not optimally reflect the predictionof prognosis. This pattern is
especially seen in patients with lobular breast carcinoma, which is the
secondmost common histologic subtype of breast cancer. A compar-
ative study on predictive value of the EWGBSP9 and Turner et al11
classifications of SN tumor load in patients with a lobular carcinoma
has not been conducted before. Although probably only long-term
follow-up studies may reveal the most optimal nodal staging defini-
tion, non-SN involvement can be regarded as a good surrogate prog-
nostic indicator, which can be assessed instantaneously. The objective
of this study, therefore, was to compare the rates of non-SN involve-
ment associatedwith SNmetastases (according to the classification by
the EWGBSP9 and Turner et al11) in patients with lobular breast
carcinoma to select the most optimal method that differentiates be-




Members of the EWGBSP that contributed to a previous multicenter
study14 were asked to participate in this study. This study group was updated
and supplemented with patient cases from several other members of this
working group, which resulted in an overlap of 10% and made this study
independent from this previous study. All contributors were asked to extract
data from their ownarchives and to reclassify the positive SNmetastases of the
tumors according to the interpretations defined by the EWGBSP9 andTurner
et al.11 A detailed, step-wise protocol; a data-extraction form (via Microsoft
Excel sheet); and digital training programs (via Microsoft PowerPoint) were
distributed to all contributors. None of those patient cases evaluated in these
training programs were included in this study. The two main differences
between these twoclassifications are thedefinitionof a cluster (which results in
different diameters of metastases) and the role of themicroanatomic location
of tumor deposits. Details of these two interpretations are listed in Table 1.
The following criteria for study inclusion had to be fulfilled. First, pa-
tients had to be diagnosed with any type of invasive lobular breast carcinoma.
Second, patients had to be diagnosed previously with a tumor-positive SN (ie,
ITC, micrometastases, or macrometastases), followed by an axillary lymph
node dissection (including six lymph nodes, additionally denoted as non-
SNs). Data extracted from the original reports included primary tumor fea-
tures (ie, diameter, lymphovascular invasion,unifocality, ormultifocality), the
number of (tumor-positive) SNs, and the number of (tumor-positive) non-
SNs. All contributors reclassified tumor-positive SNs according to both the
EWGBSP9 and Turner et al11 classifications, and they were blinded to the
status of the non-SN. The detectionmethod of thesemetastases (ie, hematox-
ylin and eosin [H&E] or immunohistochemistry) and the presence or absence
of extranodal extension also was recorded. In occurrences of discordance
between both classifications, the reason (either diameter or microanatomic
location) was recorded to evaluate the effect of these features separately.
Table 1. Main Differences in the EWGBSP9 and Turner et al11 Definitions to Classify SN Metastases
Term
Definitions
EWGBSP9 Turner et al11
Cluster Single tumor cells or clusters are arranged in a continuous manner
or separated by only a few cells distance
Cells or clusters arranged in a discontinuous manner but dispersed
homogeneously in a definable part of the lymph node should be
measured as one focus
Cells, clusters, or foci arranged in a discontinuous manner and
dispersed unevenly should be considered as one if the distance
between clusters or foci is smaller than the smallest cluster or
focus; if the distance between these cells, clusters, or foci is
larger than the smallest cluster or focus, it should be
characterized by the size of the largest cluster or focus
Three-dimensional information is used: single cluster in
corresponding areas of two consecutive sections at  0.2 mm
interval is measured as one
Confluent focus of tumor cells that are touching other tumor cells
Clusters or cells separated by a single benign cell or a spatial gap
are measured as separate clusters, except when fibroblastic
reaction of the tumor has caused this separation
Single cells represent ITC; densely crowded cells when
contiguous/touching are measured and classified according to
the largest group of contiguous/touching cells




Tumor cells localized in the parenchyma are considered
micrometastases (except with  five single cells), even if the
largest diameter is  0.2 mm
Metastatic cells in extranodal lymph vessels should not be
recorded as nodal involvement
Microanatomic location is not a factor in classification; ITC may be
found in nodal parenchyma
Metastatic cells in extranodal lymph vessels are classified as
nodal disease on the basis of size of deposit
Proliferation Mitotic activity is considered as a feature reflecting
malignant/metastatic activity
Mitotic activity is not considered
Abbreviations: EWGBSP, European Working Group for Breast Screening Pathology; ITC, isolated tumor cell.
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SN Processing
The pathologic work-up of SNs was somewhat heterogeneous, but all
laboratories used amultilevel assessment and performed immunohistochem-
istry for patient caseswith anegative SNonH&Estaining,whichwas generally
performed on multiple levels. Non-SNs were evaluated by a single to a few
H&E–stained sections without the routine use of immunohistochemistry.
Statistical Analysis
The 95% CIs were calculated by use of the Rothman spreadsheet.15
Univariate analysis with the 2 test was used to correlate covariates with
non-SN involvement. The Spearman correlation coefficient was used as a
measure of correlation between the total number of SNs and the number of
positive non-SNs. In those patient cases withmore than one SN involved, the
largest deposit was used for statistical analysis. Statistical analyses were per-
formed by using SPSS for Windows (version 13.0; SPSS, Chicago, IL). Two-
sided P values less than .05 were considered significant.
RESULTS
Clinicopathologic Features
Overall, 392 patients with invasive lobular breast carcinoma and
a positive SN were included in this study, and the median tumor size
was 2.2 cm. The median numbers of SNs and non-SN assessed per
patient were two (range, one to seven) and 15 (range, six to 50),
respectively. The overall rate of non-SN involvement was 183 (47%;
95%CI, 41.8 to 51.6) of 392 patients.
SN Staging
The originally diagnosed SN metastases were classified as ITC
(n 31; 6%), micrometastases (n 132; 26%), or macrometastases
(n  274; 54%), or they remained unclassified (n  74; 14%). The
majority of these metastases (ie, 286 [73%] of 392) were detected by
H&E staining.
Reclassification according to the definitions of the EWGBSP9
and Turner et al11 resulted in a discordance in nodal staging in 86
(22%) of 392 patients because of a difference in either diameter
(n 42; 49%), microanatomic location (n  29; 34%), or both
(n 15; 17%). This resulted in a different pN classification in 73
patients (19%). Overall, the rates of SN ITC, micrometastases, and
macrometastases were 7%, 27%, and 66% according to the interpre-
tation of the EWGBSP,9 compared with 18%, 25%, and 57% on the
basis of the definitions by Turner et al.11 Figure 1 shows some exam-
ples of metastatic deposits causing discordance between both staging
definitions. Themajority of these discordantly staged cases (40 [55%]
of 73 patients) were classified as micrometastases according to the
interpretation of the EWGBSP,9 whereas they were classified as ITC
according to the interpretation by Turner et al11 (Table 2). The rest of
these discrepancies were caused by a difference betweenmicrometas-
tases (Turner et al11) versus macrometastases (EWGBSP9; 40%) or
between ITC (Turner et al11) versus macrometastases (EWGBSP9;
5%). Taking the total number of patients into account revealed a
discordance in 40 (37%) of 107 of all patients with micrometastases
according to the EWGBSP.9 The rate of discordances in the group of
patients classifiedasmacrometastases according toEWGBSPwasonly
13% (33 of 258 patients).
Non-SN Involvement
Univariate analysis showed that the diameter of the primary






2.0 mm 100 µm
Fig 1. Examples of sentinel node (SN)
metastases from lobular breast carcinoma
that caused difficulty in nodal classifica-
tion and discordance between different
interpretations. SNs with multiple single
cells and clusters arranged in a discontin-
uous manner but dispersed homoge-
neously in a definable part of the lymph
node, classified as (A, B) micrometastases
or (C) macrometastasis according to the
European Working Group for Breast Screen-
ing Pathology (EWGBSP) interpretations9
versus ITC according to Turner et al.11 (D)
SN with a tumor cluster less than 0.2 mm
located in the parenchyma, classified as a
micrometastasis according to the EWGBSP
interpretation9 versus isolated tumor cells
according to Turner et al.11
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associated with non-SN involvement (P .002 and P .001, respec-
tively). SN features that were significantly associated with non-SN
involvement included the detectionmethod (P .001), the presence
of extracapsular extension (P  .001), SN staging according to the
EWGBSP9, aswell as Turner et al11 (P .001 for both; Table 3). There
was no significant correlation between the total number of SNs and
the number of positive non-SNs (P .32).
The rates of non-SN involvement in patients with SN ITC, mi-
crometastases, and macrometastases were 11%, 21%, and 61% ac-
cording to the interpretation of the EWGBSP,9 compared with 15%,
29%and64%onthebasisof thedefinitionsbyTurneretal11 (Table4).
None of these differences were statistically significant (P  .82,
P .21, and P .6, respectively). SN metastases with a diameter of
less than0.2mmthatwere classifiedasmicrometastaseson thebasis of
microanatomic location according to the EWGBSP9 were associated
with non-SN involvement in four (16%; 25 patient cases; 95% CI,
6.4% to 34.7%), compared with three patient cases (11%; 95% CI,
3.9% to 28.1%) with metastases with a diameter of less than 0.2 mm
located in the sinus, classified as ITC.
Table 5 shows the rates of non-SN involvement in those 73
patient cases with a discrepant classification between EWGBSP9
and Turner et al.11 The rate of non-SN involvement in the 40
patients with ITC according to Turner and micrometastases ac-
cording to EWGBSP was 20%, which is comparable to the estab-
lished rate formicrometastases. The rate of non-SN involvement in
the 29 patients with micrometastases according to Turner et al11
and macrometastases according to EWGBSP9 was 48%, which is
comparable to the established rate for macrometastases. However,
none of those four patient cases classified as having macrometas-
tases according to EWGBSP9 versus ITC according toTurner et al11
had detected non-SN involvement (Fig 1C). Overall, the EWGBSP
method to classify SN tumor load thereby better reflected the risk
of non-SN involvement than the Turner et al11 system in these
discrepant patients.
DISCUSSION
Lymph node metastases from lobular invasive breast cancer often
show a pattern with multiple scattered clusters and/or single cells
in both sinus and parenchyma of (sentinel) lymph nodes, which
complicates nodal staging. This study is the first to evaluate nodal
staging in this specific group of patients by assessing the frequency
of non-SN involvement for two different interpretations of nodal
staging guidelines.
Overall, the rates of non-SN involvement in patients with a lob-
ular breast carcinoma and SN ITC,micrometastases, ormacrometas-
tases were consistent with results from previous breast cancer studies
including all histologic subtypes.16,17 Several features of the primary
tumor (ie, diameter, lymphovascular invasion) and the SN (ie, num-
ber of involved SNs, extracapsular extension) were also significantly
associated with non-SN involvement, which is consistent with previ-
ous breast cancer studies.18-21
Table 2. Comparison of SN Staging According to the Interpretations of
EWGBSP9 and Turner et al11 Criteria in a Group of 392 Patients With
Invasive Lobular Breast Cancer
EWGBSP
Criteria9
Turner et al11 Criteria
ITC Micrometastases Macrometastases Total
ITC 27 0 0 27
Micrometastases 40 67 0 107
Macrometastases 4 29 225 258
Total 71 96 225 392
Abbreviations: EWGBSP, European Working Group for Breast Screening
Pathology; ITC, isolated tumor cell.
Table 3. Comparison of Clinicopathologic and SN Characteristics in Patients
With Lobular Breast Carcinoma Without and With Non-SN Involvement
Variable








No. % No. %
Primary tumor feature
Tumor stage
pT1 107 51 62 34 .002
pT2 89 43 102 56
pT3 13 6 19 10
Lymphovascular invasion .001
No 138 66 93 51
Yes 58 28 81 44
Unknown 13 6 9 5
Growth pattern .14
Unifocal 115 55 87 48
Multifocal 78 37 81 44
Unknown 16 8 15 8
SN feature
No. of SNs
Median 2 2 .92
Range 1-5 1-5
No. of involved SNs .07
Median 1 1
Range 1-3 1-5
Detection method  .001
H&E 130 62 156 85
Immunohistochemistry 79 38 27 15
Extracapsular extension  .001
No 159 76 103 56
Yes 38 18 77 42
Unknown 12 6 3 2
SN classification according
to EWGBSP9  .001
ITC 24 10 3 2
Micrometastases 85 41 22 12
Macrometastases 100 48 158 86
SN classification according
to Turner et al11  .001
ITC 62 30 11 6
Micrometastases 66 32 28 15
Macrometastases 81 39 144 79
No. of non-SNs .069
 10 39 19 25 14
 10 to  15 81 39 59 32
 15 89 43 99 54
Abbreviations: SN, sentinel node; H&E, hematoxylin and eosin; ITC,
isolated tumor cell; EWGBSP, European Working Group for Breast
Screening Pathology.
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SN reclassification according to the definitions of the
EWGBSP9 and Turner et al11 resulted in a different pN classifica-
tion in 73 patients (19%). Not all discrepancies resulted in a differ-
ent pN classification, because patients were staged according to the
largest metastatic deposit; for example, a patient with two macro-
metastases according to the EWGBSP interpretation9was classified
as having onemacrometastases andonemicrometastasis according
to Turner et al.11
In general, the EWGBSP9 interpretation designates more often
metastases intoahigher category than theTurner et al11 system.This is
because metastatic cell clusters that have a size compatible with ITC
areyet classifiedasmicrometastaseswhen themicroanatomic location
is in the SN parenchyma. Second, a dispersed pattern of generally
small tumor clusters or single metastatic cells is considered ITC or
micrometastases in the Turner et al11 classification depending on size
of the largest cluster, whereas these are often designatedmicrometas-
tases or macrometastases in the EWGBSP system.9 Of 107 patient
cases classified as micrometastases according to the EWGBSP defini-
tions,9 40 patients (37%) were staged as having ITC according to
Turner et al.11 This is higher than the discordance rate of 24% previ-
ously reported byCserni et al,14 whichwas expected, aswe considered
only lobularbreast cancerswhereas the studyofCserni et al14 included
all breast cancer subtypes. The discrepancy betweenmicrometastases
(Turner et al11) versusmacrometastases (EWGBSP9) or between ITC
(Turner et al11) versusmacrometastases (EWGBSP9), conversely, was
relatively limited. The main explanation for this finding is that a
substantial proportionofmacrometastases showa compact patternof
single cells and/or a fibroblastic reaction, which precludes a discrep-
ancy between both interpretations.
The risk of non-SN involvement in patients with SN ITC overall
did not differ significantly between both interpretations, a finding
similar to that of Cserni et al14 and dealing with all histologic breast
cancer types and only low volumemetastases. We demonstrated that
the interpretation of Turner et al11 is associated with a higher positive
predictive value of having non-SNmetastases after finding either ITC
or micrometastases in the SN. However, a high positive predictive
value is not desirable in these groups of patients, because the objective
is to select those patients with a limited risk of non-SN involvement,
which correlates better with results of the EWGBSP definitions.9 In
those patients with a discordant classification between both defini-
tions, the EWGBSPmethod to classify SN tumor load better reflected
the risk of non-SN involvement than the Turner system, which leads
to the conclusion that theEWGBSPmethod is better for the subgroup
of invasive lobular carcinomas. Second, the rate of non-SNmetastases
in patients with SN metastases less than 0.2 mm but located in the
parenchymawas 16%,which is relatively high comparedwith the risk
for non-SN metastases in patients with SN metastases less than 0.2
mm located in the sinus (11%). These clusters located in the paren-
chyma were designated micrometastases according to EWGBSP,9
whereas they are regarded as ITC by Turner et al.11 Although the
limited number of patients and the wide CIs do not allow definitive
conclusions, these seem to support the hypothesis that extravasation
of metastatic tumor deposits from the sinus into the parenchyma is a
sign of the potential to generate additional metastatic spread. One
must realize that the absence of a capsule deeper in the tissue block,
immediately behind these deposits that seem to be located purely in
the parenchyma, cannot be excluded. However, the potential risk of
overstaging these patient cases was reduced by serial sectioning of
the SN.
It was interesting to note that none of the four patient cases
classified as SN ITC according to Turner et al11 and asmacrometasta-
ses according to EWGBSP9 had non-SNmetastases. This could imply
that in these patient cases, the Turner11 classification may perform
better, although it is more likely that themain underlying cause is the
number of patient cases studied being too low to draw any conclu-
sions. In addition, non-SN metastases with a dispersed pattern may
have remained undetected in these cases, since non-SNs were not
routinely examined by immunohistochemistry.
Another difference between both classifications is the inter-
pretation of metastatic cells in extranodal lymph vessels without
nodal involvement. These patient cases were classified as having
nodal disease according to Turner et al,11 whereas they were clas-
sified as node negative according to the EWGBSP9 interpretation.
The effect of this difference with regard to the rate of non-SN
involvement is probably limited. In this study, it was not evaluated,
because these patient cases were not selected as having a positive
Table 4. Frequency and Comparison of Non-SN Involvement According to Two Different Interpretations of the N Staging System
SN Classification
Patients With Non-SN Involvement
DifferenceEWGBSP9 Turner et al11
No. No. Evaluated % 95% CI No. No. Evaluated % 95% CI % 95% CI
ITC 3 27 11 3.9 to 28.1 11 71 15 8.9 to 25.7 4 13.8 to 16.9
Micrometastases 22 107 21 14.0 to 29.2 28 96 29 21.0 to 38.9 9 3.3 to 20.4
Macrometastases 158 258 61 55.2 to 67.0 144 225 64 57.5 to 70.0 3 5.9 to 11.3
Abbreviations: SN, sentinel node; EWGBSP, European Working Group for Breast Screening Pathology; ITC, isolated tumor cell.
Table 5. Frequency of Non-SN Involvement for 73 Invasive Lobular
Carcinoma Cases With Dissimilar N Classification According to Two










ITC Micrometastases 40 8 20
ITC Macrometastases 4 0 0
Micrometastases Macrometastases 29 14 48
Abbreviations: SN, sentinel node; EWGBSP, European Working Group for
Breast Screening Pathology; ITC, isolated tumor cell.
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SN. The capsular and subcapsular lymphatic space on the other
hand is regarded as part of the lymph node according to both
definitions. Thesemetastatic deposits are classified as either ITC or
micrometastases, depending on size.
The definitions by Turner et al11 are superior to those by the
EWGBSP9 regarding reproducibility in small metastases (,0.92 v
0.49). However, they tend to understage high-volume metastases.
Because the EWGBSP definitions9 reflect the total metastatic tumor
load, especially in patients with lobular breast carcinoma, we suggest
using these definitions at least in patients with lobular breast carci-
noma for nodal staging to select high-risk patients that may benefit
from additional local and/or systemic therapy. Clarifications regard-
ing the measurement of nodal metastases, supplemented by visual
examples, should be included in future staging manuals (or well
worked out on Web sites) to achieve reproducible nodal staging.
Although an improved interobserver agreement does not necessarily
mean better treatment, it is required to make a better prognostic
separation. Findings from large studies assessing the effect of ITC and
micrometastases on survival will provide greater clinical evidence re-
gardingpolicieson local and systemic treatment inpatientswitheither
ITC ormicrometastases in their SNs.
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